Dave Fellows, Beacon Therapeutics CEO
Ex-Nightstar, Gyroscope and AGTC teams try again for next retinal gene therapy with $120M for Beacon Therapeutics
Life sciences investor Syncona is taking a second shot at X-linked retinitis pigmentosa, this time with Beacon Therapeutics, a retinal gene therapy startup led by …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.